Other analysts have also issued research reports about the stock. Gabelli lowered shares of Lexicon Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, March 13th. Zacks Investment Research lowered shares of Lexicon Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, January 18th. ValuEngine raised shares of Lexicon Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, March 12th. Wedbush boosted their price objective on shares of Lexicon Pharmaceuticals from $36.00 to $38.00 and gave the company an outperform rating in a research note on Monday, March 4th. Finally, Stifel Nicolaus reduced their price objective on shares of Lexicon Pharmaceuticals from $14.00 to $10.00 and set a buy rating for the company in a research note on Monday, March 25th. Six analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Lexicon Pharmaceuticals has a consensus rating of Hold and an average target price of $16.38.
Lexicon Pharmaceuticals stock traded down $0.11 during midday trading on Thursday, hitting $6.77. 350,540 shares of the stock were exchanged, compared to its average volume of 659,445. The stock has a market cap of $719.45 million, a PE ratio of -5.94 and a beta of 0.72. Lexicon Pharmaceuticals has a 52-week low of $4.25 and a 52-week high of $13.97.
Hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA grew its stake in Lexicon Pharmaceuticals by 940.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 9,934 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 8,979 shares in the last quarter. Pegasus Asset Management Inc. purchased a new position in Lexicon Pharmaceuticals in the 4th quarter worth approximately $66,000. Wealth & Pension Services Group Inc. purchased a new position in Lexicon Pharmaceuticals in the 1st quarter worth approximately $60,000. Paloma Partners Management Co purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $73,000. Finally, Federated Investors Inc. PA boosted its stake in shares of Lexicon Pharmaceuticals by 1,317.0% in the 1st quarter. Federated Investors Inc. PA now owns 12,611 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 11,721 shares in the last quarter.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Further Reading: Are all No-Load Funds Equal?
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.